Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMLNP@miR-15a
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CMLNP@miR-15a is a biomimetic, dual-targeting lipid nanoparticle (LNP) delivery system designed for the sequential delivery of microRNA-15a (miR-15a) in the treatment of multiple myeloma. The platform consists of alendronate (ALN)-functionalized LNPs encapsulated with BCMA-targeting CAR-T cell membranes. This sequential delivery mechanism utilizes ALN to home to the bone marrow via hydroxyapatite binding, followed by CAR-driven specific recognition of B-cell maturation antigen (BCMA) on multiple myeloma cells. By delivering miR-15a, the therapy aims to reprogram the tumor microenvironment, enhance CAR-T cell persistence, and overcome tumor recurrence after CAR-T cell therapy.
- Other names
- CMLNP-miR-15aCMLNP-miR15aCMLNP-miR 15a
02
Targets
BCL-2 (BCL-2 family)CDC25A (Cell division cycle 25A phosphatase)CCND1 (Cyclin D1)CCND2 (Cyclin D2)CCNE1 (Cyclin E1)PHF19 (PHD finger protein 19)VEGFA (Vascular endothelial growth factor A)miR-15a (MicroRNA 15a)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CMLNP@miR-15a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMLNP@miR-15a.